Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

BACKGROUND: The optimal timing to initiate bevacizumab (BV) therapy for recurrent glioblastoma (GBM) is currently unclear. To address this issue, we examined progression-free survival (PFS) and survival time (ST) in a large retrospective cohort of GBM patients treated with BV at different recurrence...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Piccioni, David E., Selfridge, Julia, Mody, Reema R., Chowdhury, Reshmi, Li, Sichen, Lalezari, Shadi, Wawrzynski, James, Quan, Jennifer, Zurayk, Mira, Chou, Arthur P., Sanchez, Desiree E., Liau, Linda M., Ellingson, Benjamin M., Pope, Whitney B., Nghiemphu, Phioanh L., Green, Richard M., Wang, He-jing, Yong, William H., Elashoff, Robert, Cloughesy, Timothy F., Lai, Albert
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2014
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4022228/
https://ncbi.nlm.nih.gov/pubmed/24627236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou028
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars